| Identification | Back Directory | [Name]
Nafarelin Acetate | [CAS]
86220-42-0 | [Synonyms]
NAFARELIN ACETATE
Nafarelin impurity
NAFARELIN ACETATE HYDRATE
Nafarelin Acetate n-Hydrate
Nafarelin acetate naphthalene
Nafarelin acetate salt hydrate
Nafarelin Acetate Hydrate (1:x:x)
Luteinizing hormone-releasing factor (pig), 6-(3-(2-naphthalenyl)-D-alanine)-, acetate (salt), hydrate
Luteinizing hormone-releasing factor (swine), 6-(3-(2-naphthalenyl)-D-alanine)-, acetate (salt), hydrate
5-OXO-L-PROLYL-L-HISTIDYL-L-TRYPTOPHYL-L-SERYL-L-TYROSYL-3-(2-NAPHTHYL)-D-ALANYL-L-LEUCYL-L-ARGINYL-L-PROLYLGLYCINAMIDE ACETATE HYDRATE
5-OXO-L-PROLYL-L-HISTIDYL-L-TRYPTOPHYL-L-SERYL-L-TYROSYL-3-(2-NAPHTHYL)-D-ALANYL-L-LEUCYL-L-ARGINYL-L-PROLYLGLYCINAMIDE ACETATE HYDRATE
5-Oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-3-(2-naphthyl)-D-alanyl-L-leucyl-L-arginyl-L-prolylglycinamide acetate salt hydrate | [EINECS(EC#)]
253-368-1 | [Molecular Formula]
C68H89N17O16 | [MDL Number]
MFCD00895733 | [MOL File]
86220-42-0.mol | [Molecular Weight]
1400.54 |
| Hazard Information | Back Directory | [Description]
Nafarelin acetate is a synthetic decapeptide agonist analog of the natural
gonadotropin-releasing hormone, differing in the amino acid at position 6 where
D-naphthylalanine has been substituted for glycine. This substitution gives nafarelin
greater potency and a substantially longer half-life than the endogenous hormone.
Nafarelin acetate administered as a nasal spray, suppresses estrogen levels on repeated
dosing and is indicated for the management of endometriosis. It also has orphan drug
status for use in precocious puberty. | [Originator]
Syntex (USA) | [Uses]
LHRH agonist. | [Uses]
Nafarelin Acetate is a gonadotropin-releasing hormone agonist. Treatment with Nafarelin improves sleep disturbances and anxiety-depression. Nafarelin is also used in the treatment of estrogen-dependent gynecologic disorders such as endometriosis and uterine leiomyomas. | [Manufacturing Process]
In the reaction vessel of a Beckman 990 Peptide Synthesizer was placed 0.8 g
(0.8 mmol) of benzhydrylamino-polystyrene-divinylbenzene resin (Lab
Systems, Inc.) as described by Rivaille, supra. Amino acids were added
sequentially to this resin by means of the usual methods of Boc-strategy of
peptide synthesis on above copolymer.
The resin was coupled sequentially with a 2.5 molar excess of each protected amino acid and DCC. Thus, the resin was treated during successive coupling
cycles with 0.433 g Boc-Gly-OH, 0.432 g Boc-Pro-OH, 0.857 g Boc-Arg(Tosyl)-
OH, 0.462 g Boc-Leu-OH, 0,504 g Boc-3-(2-naphthyl)-D-alanine and 0.272 g
1-hydroxybenzotriazole, 0.724 g N-Boc, O-2-bromobenzoyloxycarbonyl-Ltyrosine, 0.59 g Boc-Ser(Benzyl)-OH, 0.608 g Boc-Trp-OH, 0.654 g BocHis(Tosyl)-OH and 0.524 g pyroglutamic acid. A coupling cycle for one amino
acid and completeness of the reaction is checked by the ninhydrin method of
E. Kaiser, et al., Anal. Biochem., 34, 595 (1970).
The resin was removed from the reaction vessel, washed with CH2Cl2, and
dried in vacuo to yield 2.0 g of protected polypeptide resin.
The polypeptide product was simultaneously removed from the resin and
completely deprotected by treatment with anhydrous liquid HF. A mixture of
2.0 g of protected polypeptide resin and 2 mL of anisole (scavenger) in a KelF reaction vessel was treated with 20 mL of redistilled (from CoF3) anhydrous
liquid HF at 0°C for 30 minutes. The HF was evaporated under vacuum and
the residue of (pyro)-Glu-His-Trp-Ser-Tyr-3-(2-naphthyl)-D-alanyl-Leu-ArgPro-Gly-NH2,as its HF salt, was washed with ether. The residue was then
extracted with glacial acetic acid. The acetic acid extract was lyophilized to
yield 0.8 g of crude material. The crude polypeptide was loaded on a 4x40
cm. Amberlite XAD-4 column (polystyrene-4% divinylbenzene copolymer) and
eluted with a concave gradient from water (0.5 L) to ethanol (1 L). The tubes
containing fractions from effluent volume 690 mL to 1,470 mL were pooled
and stripped to dryness to yield 490 mg of partially purified polypeptide.
A 150 mg sample of the partially purified product was subjected to partition
chromatography on a 3 times 50 cm. column of Sephadex G-25 using the
solvent system 1-butanol/toluene/acetic acid/water containing 1.5% pyridine
in the ratios 10:15:12:18. The pure fractions were pooled on the basis of thin
layer chromatography (silica gel; BuOH/H2O/HOAc/EtOAc; 1:1:1:1) and HPLC
(5 micron, reverse phase, octadecylsilyl packing; 40% 0.03 M NH4OAc/60%
acetonitrile). The desired product came off the column in fractions from
effluent volume 1,000 mL to 1,400 mL (Rf 0.1). The pure fractions were
pooled, stripped to dryness, taken up in H2O, and lyophilized to yield 57 mg of
pure pyro-glutamyl-histidyl-tryptophylseryl-tyrosyl-3-(2-naphthyl)-D-alanylleucyl-arginylprolyl-glycinamide, as its acetic acid addition salt, [α]D25-27.4°
(c 0.9, HOAc), m.p. 185°-193°C (dec.). | [Brand name]
Synarel (Searle). | [Therapeutic Function]
Gonadotropic | [Clinical Use]
Nafarelin acetate, contains D Nal(2)6 [Nal = 3-(2-naphthyl)-Ala] in place of Gly6, but the C-terminus, Gly10-NH2, is identical
with natural GnRH. Nafarelin acetate is available as a 0.2% nasal spray for the relief
of endometriosis. Estrogen, of course, is needed for the growth of endometrial tissue; thus, decreased estrogen leads to shrinkage of errant endometrial tissue. The observed side effects of nafarelin acetate are related to falling estrogen levels and include decreased libido,
amenorrhea, hot flashes, and vaginal dryness. When used consistently, nafarelin acetate will
inhibit ovulation and stop menstruation.
Nafarelin acetate also is used in children, male and female, for the treatment of central
precocious puberty. By suppressing the release of LH, the estradiol or testosterone levels fall to
prepubertal levels; early secondary sexual development is arrested, linear growth and skeletal
maturation are slowed, and in girls, menstruation stops. |
|
| Company Name: |
LGM Pharma
|
| Tel: |
1-(800)-881-8210 |
| Website: |
www.lgmpharma.com |
|